- Home
- IOT vs TEVA Comparison
IOT vs TEVA Comparison
Compare IOT & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOT
- TEVA
- Stock Information
- Founded
- IOT 2015
- TEVA 1901
- Country
- IOT United States
- TEVA Israel
- Employees
- IOT N/A
- TEVA N/A
- Industry
- IOT Retail: Computer Software & Peripheral Equipment
- TEVA Biotechnology: Pharmaceutical Preparations
- Sector
- IOT Technology
- TEVA Health Care
- Exchange
- IOT Nasdaq
- TEVA Nasdaq
- Market Cap
- IOT 25.6B
- TEVA 23.7B
- IPO Year
- IOT 2021
- TEVA N/A
- Fundamental
- Price
- IOT $46.86
- TEVA $21.92
- Analyst Decision
- IOT Buy
- TEVA Buy
- Analyst Count
- IOT 14
- TEVA 7
- Target Price
- IOT $50.86
- TEVA $22.43
- AVG Volume (30 Days)
- IOT 2.9M
- TEVA 9.7M
- Earning Date
- IOT 03-06-2025
- TEVA 01-29-2025
- Dividend Yield
- IOT N/A
- TEVA N/A
- EPS Growth
- IOT N/A
- TEVA N/A
- EPS
- IOT N/A
- TEVA N/A
- Revenue
- IOT $1,179,183,000.00
- TEVA $16,772,000,000.00
- Revenue This Year
- IOT $33.46
- TEVA $5.74
- Revenue Next Year
- IOT $23.26
- TEVA $4.46
- P/E Ratio
- IOT N/A
- TEVA N/A
- Revenue Growth
- IOT 39.11
- TEVA 9.81
- 52 Week Low
- IOT $27.14
- TEVA $10.86
- 52 Week High
- IOT $57.51
- TEVA $22.80
- Technical
- Relative Strength Index (RSI)
- IOT 53.60
- TEVA 61.44
- Support Level
- IOT $42.36
- TEVA $20.15
- Resistance Level
- IOT $46.78
- TEVA $22.10
- Average True Range (ATR)
- IOT 1.54
- TEVA 0.62
- MACD
- IOT 0.49
- TEVA -0.13
- Stochastic Oscillator
- IOT 100.00
- TEVA 66.79
About IOT Samsara Inc.
Samsara Inc provides an end-to-end solution for operations: The solution connects physical operations data to the Connected Operations Cloud, which consists of the Data Platform and Application. Geographically, it derives a majority of its revenue from the United States.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.